Denali Therapeutics Inc. (DNLI) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Denali Therapeutics Inc. (DNLI) Bundle
Evaluate Denali Therapeutics Inc. (DNLI) financial outlook like an expert! This (DNLI) DCF Calculator provides pre-filled financial data and offers the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your predictions.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.7 | 335.7 | 48.7 | 108.5 | 330.5 | 507.8 | 780.1 | 1,198.4 | 1,841.0 | 2,828.2 |
| Revenue Growth, % | 0 | 1158.19 | -85.5 | 122.9 | 204.74 | 53.62 | 53.62 | 53.62 | 53.62 | 53.62 |
| EBITDA | -205.2 | 62.7 | -287.2 | -330.4 | -180.0 | -341.0 | -523.8 | -804.7 | -1,236.3 | -1,899.2 |
| EBITDA, % | -769.15 | 18.69 | -590.12 | -304.58 | -54.45 | -67.15 | -67.15 | -67.15 | -67.15 | -67.15 |
| Depreciation | 8.0 | 6.2 | 5.6 | 7.0 | 16.7 | 55.7 | 85.6 | 131.5 | 202.0 | 310.3 |
| Depreciation, % | 29.95 | 1.84 | 11.53 | 6.48 | 5.06 | 10.97 | 10.97 | 10.97 | 10.97 | 10.97 |
| EBIT | -213.2 | 56.5 | -292.8 | -337.4 | -196.7 | -348.0 | -534.6 | -821.3 | -1,261.7 | -1,938.2 |
| EBIT, % | -799.1 | 16.85 | -601.65 | -311.07 | -59.51 | -68.53 | -68.53 | -68.53 | -68.53 | -68.53 |
| Total Cash | 415.4 | 1,469.7 | 865.4 | 1,336.2 | 1,034.5 | 507.8 | 780.1 | 1,198.4 | 1,841.0 | 2,828.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 1.2 | 9.3 | 3.4 | 12.3 | 18.9 | 29.0 | 44.6 | 68.5 |
| Account Receivables, % | 0 | 0 | 2.52 | 8.56 | 1.03 | 2.42 | 2.42 | 2.42 | 2.42 | 2.42 |
| Inventories | .0 | .0 | .0 | -5.0 | .0 | -4.7 | -7.2 | -11.0 | -17.0 | -26.1 |
| Inventories, % | 0 | 0 | 0 | -4.61 | 0 | -0.92197 | -0.92197 | -0.92197 | -0.92197 | -0.92197 |
| Accounts Payable | 2.6 | 1.1 | 4.8 | 2.8 | 9.5 | 25.7 | 39.5 | 60.6 | 93.1 | 143.0 |
| Accounts Payable, % | 9.71 | 0.31907 | 9.82 | 2.57 | 2.87 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 |
| Capital Expenditure | -17.9 | -3.1 | -8.5 | -17.8 | -12.9 | -107.6 | -165.2 | -253.8 | -390.0 | -599.1 |
| Capital Expenditure, % | -67.17 | -0.92207 | -17.47 | -16.44 | -3.91 | -21.18 | -21.18 | -21.18 | -21.18 | -21.18 |
| Tax Rate, % | -0.02066201 | -0.02066201 | -0.02066201 | -0.02066201 | -0.02066201 | -0.02066201 | -0.02066201 | -0.02066201 | -0.02066201 | -0.02066201 |
| EBITAT | -212.8 | 55.9 | -292.2 | -337.4 | -196.7 | -346.9 | -533.0 | -818.8 | -1,257.8 | -1,932.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -220.1 | 57.5 | -292.6 | -353.3 | -185.4 | -386.8 | -602.9 | -926.3 | -1,423.0 | -2,186.0 |
| WACC, % | 10.91 | 10.91 | 10.91 | 10.91 | 10.91 | 10.91 | 10.91 | 10.91 | 10.91 | 10.91 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3,760.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2,230 | |||||||||
| Terminal Value | -25,024 | |||||||||
| Present Terminal Value | -14,911 | |||||||||
| Enterprise Value | -18,672 | |||||||||
| Net Debt | -75 | |||||||||
| Equity Value | -18,597 | |||||||||
| Diluted Shares Outstanding, MM | 137 | |||||||||
| Equity Value Per Share | -135.38 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Denali Therapeutics Inc. (DNLI)’s financial data pre-filled to accelerate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive Data: Denali Therapeutics Inc.'s (DNLI) historical financial statements and pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Insights: Instantly view Denali's intrinsic value recalculating as inputs change.
- Intuitive Visuals: Dashboard graphs showcase valuation results and important metrics clearly.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the prebuilt Excel template featuring Denali Therapeutics Inc.'s (DNLI) data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see recalculated results, including Denali Therapeutics Inc.'s (DNLI) intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the outputs.
Why Choose This Calculator for Denali Therapeutics Inc. (DNLI)?
- Comprehensive Tool: Features DCF, WACC, and in-depth financial ratio analyses all in one platform.
- Customizable Inputs: Modify the highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes Denali Therapeutics' intrinsic value and Net Present Value.
- Preloaded Data: Access to historical and projected data for precise analysis.
- Professional Quality: Perfect for financial analysts, investors, and consultants in the biotech sector.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Denali Therapeutics Inc. (DNLI) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Denali Therapeutics Inc. (DNLI).
- Consultants: Deliver professional valuation insights on Denali Therapeutics Inc. (DNLI) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Denali Therapeutics Inc. (DNLI) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Denali Therapeutics Inc. (DNLI).
What the Template Contains
- Comprehensive DCF Model: Editable template featuring intricate valuation calculations.
- Real-World Data: Denali Therapeutics Inc.'s (DNLI) historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore different scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables providing clear, actionable results.